RMD Financials

Income Statement
MetricQ1 2027Q4 2026Q3 2026Q2 2026Q1 2026
Revenue
1.4B
-3.3%
1.5B
+2.3%
1.4B
+0.6%
1.4B
+6.5%
1.3B
Cost of Revenue
544.2M
-8.4%
594.1M
+11.6%
532.6M
-0.7%
536.3M
+3.5%
517.9M
Gross Profit
870.6M
+0.1%
869.5M
-3.3%
898.8M
+1.4%
886.5M
+8.4%
817.7M
Operating Expenses
417.6M
-0.8%
420.8M
+5.5%
399.0M
+1.1%
394.9M
+6.4%
371.1M
R&D
102.9M
-2.7%
105.7M
+12.2%
94.3M
+3.6%
91.0M
+1.7%
89.5M
SG&A
314.7M
+6.2%
296.3M
+3.7%
285.7M
+2.6%
278.4M
-1.2%
281.6M
Operating Income
453.0M
+1.0%
448.7M
-10.2%
499.8M
+1.7%
491.7M
+10.1%
446.5M
EBITDA
494.7M
+0.3%
493.5M
-11.7%
558.8M
+2.1%
547.5M
+10.8%
494.2M
Net Income
418.4M
+9.1%
383.4M
-3.8%
398.7M
+1.6%
392.6M
+12.6%
348.5M
EPS (Basic)
$2.93
+10.6%
$2.65
-3.3%
$2.74
+1.9%
$2.69
+13.0%
$2.38
EPS (Diluted)
$2.92
+10.6%
$2.64
-3.6%
$2.74
+2.2%
$2.68
+13.1%
$2.37
Shares (Diluted)
143.4M
-1.2%
145.2M
-0.3%
145.7M
-0.4%
146.4M
-0.4%
146.9M
ResMed (RMD) — Financials